Correction Correction: Supplementary drug treatment to reduce weight in adolescents with severe obesity Norwegian Johannes Rolin, Rønnaug Astri Ødegård, Viktoria Vedeler Amundsen, Unni Mette Stamnes Köpp, Ane Kokkvoll, Pétur Benedikt Júlíusson, Jøran Hjelmesæth About the authors See All Articles Johannes Rolin See All Articles Rønnaug Astri Ødegård See All Articles Viktoria Vedeler Amundsen See All Articles Unni Mette Stamnes Köpp See All Articles Ane Kokkvoll See All Articles Pétur Benedikt Júlíusson See All Articles Jøran Hjelmesæth Orcid () sporsmal_grey_rgb Article Tidsskr Nor Legeforen 2022; 142: 1250–1. On page 1250 of issue no. 14/2022 of the Journal of the Norwegian Medical Association, the following should be written in the English version of the article: Orlistat (Xenical) is not approved for the treatment of obesity in children aged 12 years or older, and is associated with a small weight-reducing effect on average (< 3 %) and unpleasant side effects (5). We apologise for the error, which has been corrected online. Related articles Supplementary drug treatment to reduce weight in adolescents with severe obesity Comments ( 0 ) Dette kommentarfeltet modereres, men kommentarer blir ikke redaksjonelt behandlet ut over å sikre at de følger retningslinjer for vårt kommentarfelt. This article was published more than 12 months ago and we have therefore closed it for new comments. Published: 12 January 2023 Tidsskr Nor Legeforen 12 January 2023 Vol. 143. doi: 10.4045/tidsskr.23.0028 Copyright: ©️️ Tidsskriftet 2025 PlumX Published: 12 January 2023 Tidsskr Nor Legeforen 2023 Vol. 143. doi: 10.4045/tidsskr.23.0028 Copyright: ©️️ Tidsskriftet 2025 Plum Print visual indicator of research metrics PlumX Metrics PDF If you do not see the PDF file or want to save the file, you can right-click on the PDF icon. Select «Save target / file as ...» and then retrieve the PDF file in, for example, Acrobat Reader. Print Recent Articles